1. Home
  2. MFA vs COLL Comparison

MFA vs COLL Comparison

Compare MFA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFA Financial Inc.

MFA

MFA Financial Inc.

HOLD

Current Price

$9.60

Market Cap

976.0M

Sector

Real Estate

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$49.13

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFA
COLL
Founded
1997
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
976.0M
1.5B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
MFA
COLL
Price
$9.60
$49.13
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$10.96
$47.50
AVG Volume (30 Days)
1.1M
515.8K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
15.00%
N/A
EPS Growth
N/A
N/A
EPS
0.86
1.63
Revenue
$279,011,000.00
$757,067,000.00
Revenue This Year
N/A
$26.35
Revenue Next Year
$14.85
$3.67
P/E Ratio
$11.17
$29.92
Revenue Growth
N/A
26.34
52 Week Low
$7.85
$23.23
52 Week High
$11.08
$49.16

Technical Indicators

Market Signals
Indicator
MFA
COLL
Relative Strength Index (RSI) 59.24 71.79
Support Level $9.45 $47.86
Resistance Level $9.72 $49.16
Average True Range (ATR) 0.15 1.33
MACD 0.01 -0.15
Stochastic Oscillator 83.64 92.01

Price Performance

Historical Comparison
MFA
COLL

About MFA MFA Financial Inc.

MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: